NTRK gene fusion–driven neoplasms: molecular mechanisms, diagnosis, and targeted therapy – a narrative review
Romanian Medical Journal · 30.06.2026 · 73 (2) · 259
DOI: 10.37897/rmj.2026.2.18 ↗Kurz gefasst
Fachartikel in der Zeitschrift Romanian Medical Journal, online erschienen am 19.06.2026. Verfasst von Cristina Alexandra Manea und 6 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are rare but clinically actionable oncogenic events identified across diverse pediatric and adult solid tumors. By generating ligand-independent TRK fusion kinases (TRKA, TRKB, or TRKC), these rearrangements activate downstream pathways such as RAS/MAPK, PI3K/AKT/mTOR, and PLCγ, driving tumor growth and survival. Although NTRK fusions occur at low frequency in most common adult malignancies, they are highly enriched in selected rare tumors, including infantile fibrosarcoma, cellular congenital mesoblastic nephroma, and secretory carcinomas of the salivary gland and breast. The tumor-agnostic regulatory approvals of first-generation TRK inhibitors, larotrectinib and entrectinib, have transformed NTRK fusions into practical predictive biomarkers and have made accurate detection a priority in precision oncology. This narrative review summarizes the molecular basis of NTRK fusion-driven neoplasms, tumor contexts in which testing is most informative, strengths and limitations of available diagnostic methods, including pan-TRK immunohistochemistry, FISH, RT-PCR, and DNA- versus RNA-based next-generation sequencing, and clinical evidence supporting TRK-targeted therapy. Particular attention is given to diagnostic pitfalls, the need for molecular confirmation of screening results, mechanisms of acquired resistance, and the emerging role of next-generation TRK inhibitors such as selitrectinib and repotrectinib. We also propose a pragmatic multidisciplinary workflow integrating molecular diagnostics, systemic therapy, and surgery when appropriate.
Zitieren
APA
Manea, C. A., Badiu, D. C., Zgura, A., Smarandache, C. G., Serban, D., Grigorean, V. T., & Botnarciuc, V. (2026). NTRK gene fusion–driven neoplasms: molecular mechanisms, diagnosis, and targeted therapy – a narrative review. Romanian Medical Journal, 73(2), 259. https://doi.org/10.37897/rmj.2026.2.18
Vancouver
Manea CA, Badiu DC, Zgura A, Smarandache CG, Serban D, Grigorean VT, et al. NTRK gene fusion–driven neoplasms: molecular mechanisms, diagnosis, and targeted therapy – a narrative review. Romanian Medical Journal. 2026;73(2):259. doi:10.37897/rmj.2026.2.18
BibTeX
@article{Manea2026,
author = {Manea, Cristina Alexandra and Badiu, Dumitru Cristinel and Zgura, Anca and Smarandache, Catalin Gabriel and Serban, Dragos and Grigorean, Valentin Titus and Botnarciuc, Vladimir},
title = {NTRK gene fusion–driven neoplasms: molecular mechanisms, diagnosis, and targeted therapy – a narrative review},
journal = {Romanian Medical Journal},
year = {2026},
volume = {73},
number = {2},
pages = {259},
doi = {10.37897/rmj.2026.2.18}
}
EUVIMED